merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>The primary reason is that Eli Lilly's vials are FDA-approved and perceived as safer, despite the lower price of compounded drugs.</answer>

<question_number>2</question_number>
<answer>Eli Lilly's strategy challenges telehealth companies by offering a direct, FDA-approved alternative through its own telehealth platform, LillyDirect.</answer>

<question_number>3</question_number>
<answer>The implicit risk is that compounded drugs have far less oversight and are not controlled for safety, quality, and effectiveness.</answer>

<question_number>4</question_number>
<answer>Eli Lilly's decision is a strategic move to regain market share from compounding pharmacies, even if it means undercutting its own pen sales.</answer>

<question_number>5</question_number>
<answer>The FDA's shortage list is significant because once tirzepatide is off the list, there should be no space for mass compounders, according to Eli Lilly.</answer>

<question_number>6</question_number>
<answer>Eli Lilly's pricing strategy reflects a trend towards direct-to-consumer sales, removing third-party supply chain entities to offer transparent pricing.</answer>

<question_number>7</question_number>
<answer>The article suggests that Medicare's stance could lead to more older patients using Zepbound vials, despite potential risks like muscle loss.</answer>

<question_number>8</question_number>
<answer>The article implies that patients may perceive Eli Lilly's vials as a safer option compared to compounded tirzepatide.</answer>

<question_number>9</question_number>
<answer>The regulatory status that allows compounding pharmacies to produce alternatives is the FDA's shortage list, which includes tirzepatide.</answer>

<question_number>10</question_number>
<answer>Eli Lilly is using lower pricing to regain market share, signaling to the compounded drug market that they will compete on price.</answer>